Doxycycline and its derivative, COL-3, decrease dyskinesia induced by l-DOPA in hemiparkinsonian rats.

Mariza Bortolanza Glauce C do Nascimento Rita Raisman-Vozari Elaine Del-Bel

Published in: British journal of pharmacology (2021)

The present study demonstrates the anti-dyskinetic potential of doxycycline and its analogue compound COL-3 in hemiparkinsonian rats. Given the long-established and safe clinical use of doxycycline, this study suggests that these drugs might be tested to reduce or prevent l-DOPA-induced dyskinesia in Parkinson's patients.

Keyphrases

end stage renal disease
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
high glucose
drug induced
climate change
patient reported outcomes
endothelial cells
stress induced